The main outcomes of the Programa Español para Tratamiento de Hemopatías (PETHEMA)-acute lymphoblastic leukaemia (ALL)-Ph-08 trial were described and compared with those of the historical PETHEMA-CSTIBES02 trial. The trials differed in imatinib dose (600 vs. 400 mg/d) and amount of chemotherapy (one vs. two consolidation cycles) before stem cell transplantation (SCT). All patients (n = 29) enrolled in the ALL-Ph-08 trial achieved complete remission (CR) (vs. 90% in CSTIBES02), and SCT was performed in CR in 90% (vs. 78%). The reduction in early death, relapse before SCT and transplant-related mortality observed in the ALL-Ph-08 trial resulted in an improved 2-year event-free survival (63% vs. 37%, P = 0·009). © 2012 Blackwell Publishing Ltd.
- Acute lymphoblastic leukaemia
- Philadelphia chromosome
Ribera, J. M., García, O., Montesinos, P., Brunet, S., Abella, E., Barrios, M., González-Campos, J., Bravo, P., Amigo, M. L., & Hernández-Rivas, J. M. (2012). Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. British Journal of Haematology, 159(1), 78-81. https://doi.org/10.1111/j.1365-2141.2012.09240.x